Treatment of coats' disease with combination therapy of intravitreal bevacizumab, laser photocoagulation, and sub-tenon corticosteroids

Julia Sein, Jonathan H. Tzu, Timothy G. Murray, Audina Berrocal

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

BACKGROUND AND OBJECTIVE: The authors investigate the efficacy of combination treatment with laser photocoagulation, intravitreal bevacizumab (IVB) (Avastin; Genentech, South San Francisco, CA), and sub-Tenon corticosteroids in Coats' disease. PATIENTS AND METHODS: Patient records at the Bascom Palmer Eye Institute were reviewed from August 2002 to January 2014. Primary outcome measures were anatomic success, globe salvage, and final visual acuity. RESULTS: Of the 26 patients (26 eyes) reviewed, 20 patients had stage 3A2, four patients had stage 3A1, and two patients had stage 2A. Mean follow-up time was 2.26 years. The median number of applications was five and three for laser and IVB, respectively. Five patients received sub-Tenon triamcinolone injections. Global salvage was achieved in all patients. Final visual acuity outcomes were reasonable: 20/20 to 20/50 in five patients, 20/60 to 20/100 in five patients, and 20/200 or less in 16 patients. CONCLUSION: Intravitreal injections of bevacizumab used in combination with repetitive laser photocoagulation therapy yielded anatomic success, global salvage, and reasonable visual acuity outcomes.

Original languageEnglish (US)
Pages (from-to)443-449
Number of pages7
JournalOphthalmic Surgery Lasers and Imaging Retina
Volume47
Issue number5
DOIs
StatePublished - May 1 2016

Fingerprint

Retinal Telangiectasis
Light Coagulation
Adrenal Cortex Hormones
Lasers
Visual Acuity
Therapeutics
Bevacizumab
Triamcinolone
Intravitreal Injections
San Francisco
Laser Therapy

ASJC Scopus subject areas

  • Ophthalmology
  • Surgery

Cite this

Treatment of coats' disease with combination therapy of intravitreal bevacizumab, laser photocoagulation, and sub-tenon corticosteroids. / Sein, Julia; Tzu, Jonathan H.; Murray, Timothy G.; Berrocal, Audina.

In: Ophthalmic Surgery Lasers and Imaging Retina, Vol. 47, No. 5, 01.05.2016, p. 443-449.

Research output: Contribution to journalArticle

@article{9398a94ab0de40a0a7e232a339088265,
title = "Treatment of coats' disease with combination therapy of intravitreal bevacizumab, laser photocoagulation, and sub-tenon corticosteroids",
abstract = "BACKGROUND AND OBJECTIVE: The authors investigate the efficacy of combination treatment with laser photocoagulation, intravitreal bevacizumab (IVB) (Avastin; Genentech, South San Francisco, CA), and sub-Tenon corticosteroids in Coats' disease. PATIENTS AND METHODS: Patient records at the Bascom Palmer Eye Institute were reviewed from August 2002 to January 2014. Primary outcome measures were anatomic success, globe salvage, and final visual acuity. RESULTS: Of the 26 patients (26 eyes) reviewed, 20 patients had stage 3A2, four patients had stage 3A1, and two patients had stage 2A. Mean follow-up time was 2.26 years. The median number of applications was five and three for laser and IVB, respectively. Five patients received sub-Tenon triamcinolone injections. Global salvage was achieved in all patients. Final visual acuity outcomes were reasonable: 20/20 to 20/50 in five patients, 20/60 to 20/100 in five patients, and 20/200 or less in 16 patients. CONCLUSION: Intravitreal injections of bevacizumab used in combination with repetitive laser photocoagulation therapy yielded anatomic success, global salvage, and reasonable visual acuity outcomes.",
author = "Julia Sein and Tzu, {Jonathan H.} and Murray, {Timothy G.} and Audina Berrocal",
year = "2016",
month = "5",
day = "1",
doi = "10.3928/23258160-20160419-07",
language = "English (US)",
volume = "47",
pages = "443--449",
journal = "Ophthalmic Surgery Lasers and Imaging Retina",
issn = "2325-8160",
publisher = "Slack Incorporated",
number = "5",

}

TY - JOUR

T1 - Treatment of coats' disease with combination therapy of intravitreal bevacizumab, laser photocoagulation, and sub-tenon corticosteroids

AU - Sein, Julia

AU - Tzu, Jonathan H.

AU - Murray, Timothy G.

AU - Berrocal, Audina

PY - 2016/5/1

Y1 - 2016/5/1

N2 - BACKGROUND AND OBJECTIVE: The authors investigate the efficacy of combination treatment with laser photocoagulation, intravitreal bevacizumab (IVB) (Avastin; Genentech, South San Francisco, CA), and sub-Tenon corticosteroids in Coats' disease. PATIENTS AND METHODS: Patient records at the Bascom Palmer Eye Institute were reviewed from August 2002 to January 2014. Primary outcome measures were anatomic success, globe salvage, and final visual acuity. RESULTS: Of the 26 patients (26 eyes) reviewed, 20 patients had stage 3A2, four patients had stage 3A1, and two patients had stage 2A. Mean follow-up time was 2.26 years. The median number of applications was five and three for laser and IVB, respectively. Five patients received sub-Tenon triamcinolone injections. Global salvage was achieved in all patients. Final visual acuity outcomes were reasonable: 20/20 to 20/50 in five patients, 20/60 to 20/100 in five patients, and 20/200 or less in 16 patients. CONCLUSION: Intravitreal injections of bevacizumab used in combination with repetitive laser photocoagulation therapy yielded anatomic success, global salvage, and reasonable visual acuity outcomes.

AB - BACKGROUND AND OBJECTIVE: The authors investigate the efficacy of combination treatment with laser photocoagulation, intravitreal bevacizumab (IVB) (Avastin; Genentech, South San Francisco, CA), and sub-Tenon corticosteroids in Coats' disease. PATIENTS AND METHODS: Patient records at the Bascom Palmer Eye Institute were reviewed from August 2002 to January 2014. Primary outcome measures were anatomic success, globe salvage, and final visual acuity. RESULTS: Of the 26 patients (26 eyes) reviewed, 20 patients had stage 3A2, four patients had stage 3A1, and two patients had stage 2A. Mean follow-up time was 2.26 years. The median number of applications was five and three for laser and IVB, respectively. Five patients received sub-Tenon triamcinolone injections. Global salvage was achieved in all patients. Final visual acuity outcomes were reasonable: 20/20 to 20/50 in five patients, 20/60 to 20/100 in five patients, and 20/200 or less in 16 patients. CONCLUSION: Intravitreal injections of bevacizumab used in combination with repetitive laser photocoagulation therapy yielded anatomic success, global salvage, and reasonable visual acuity outcomes.

UR - http://www.scopus.com/inward/record.url?scp=84983384125&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983384125&partnerID=8YFLogxK

U2 - 10.3928/23258160-20160419-07

DO - 10.3928/23258160-20160419-07

M3 - Article

C2 - 27183548

AN - SCOPUS:84983384125

VL - 47

SP - 443

EP - 449

JO - Ophthalmic Surgery Lasers and Imaging Retina

JF - Ophthalmic Surgery Lasers and Imaging Retina

SN - 2325-8160

IS - 5

ER -